Research Summary

PD-1 and PD-L1 inhibitors are a class of immunotherapy drugs that enhance the body’s immune response against cancer by blocking the interaction between the programmed cell death protein 1 (PD-1) on T-cells and its ligand PD-L1 on tumor cells. This checkpoint blockade prevents tumors from evading immune detection, allowing T-cells to recognize and attack cancer cells more effectively. Widely used in the treatment of various cancers such as melanoma, lung cancer, and renal cell carcinoma, PD-1 and PD-L1 inhibitors have transformed oncology by offering targeted, durable, and often less toxic treatment options compared to conventional chemotherapy.

This report conducts an in-depth assessment of the global PD-1 and PD-L1 Inhibitors market from both macro and micro perspectives, covering current market conditions, the competitive landscape, and the key drivers and constraints influencing industry development. It provides a systematic analysis of market size, price trends, and future growth prospects for global PD-1 and PD-L1 Inhibitors markets, while placing particular emphasis on evaluating major manufacturers in terms of market share, product specifications, competitive advantages, pricing levels, sales volumes, revenues and gross margins. In addition, the report further analyzes the development status and future outlook of different PD-1 and PD-L1 Inhibitors product segments and downstream application fields. From a regional perspective, the analysis covers 12 key countries and regions—China, the United States, Germany, Japan, France, the United Kingdom, Italy, South Korea, Southeast Asia, India, Latin America, and the Middle East & Africa—highlighting regional development trends across the industry.

From a competitive landscape perspective, the global PD-1 and PD-L1 Inhibitors market is characterized by a relatively high level of competition, with leading players holding clear advantages. Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Hengrui Medicine, Beigene, Innovent Biologics, Junshi Biosciences, Akeso, Alphamab Oncology and other companies are among the major market leaders. Based on factors such as company revenue scale, market coverage, and overall competitive strength, the market can be divided into three tiers. The first tier consists of global leading companies, which together are expected to account for approximately % of the market in 2025, benefiting from strong advantages in technological capabilities, customer resources, and global footprint. The second tier includes companies with a certain level of market share and industry influence, collectively accounting for around %, and continues to catch up through differentiated products, regional market expansion, or alternative technological approaches. The third tier is composed of companies with more fragmented market shares, primarily focusing on local or niche application markets, with relatively smaller overall sales volumes.

This study uses 2025 as the base year to conduct a systematic quantitative analysis of the PD-1 and PD-L1 Inhibitors industry. The research first reviews historical market data from 2021 to 2025, with a focus on changes in industry scale, growth momentum, and structural evolution. Data for 2025 are compiled based on the latest primary research and authoritative secondary sources, serving as the core benchmark for the overall analysis and forecasting. On this basis, combining historical trends, industry cycle characteristics, and the most recent market information for 2025, quantitative forecasting models are developed to estimate and simulate the industry's development from 2026 to 2033, in order to assess its medium- to long-term growth potential and development trajectory.

This report is fundamentally data-driven, offering robust analytical support to help companies uncover potential growth opportunities, identify variations across regional markets, and dynamically adapt product, branding, and channel strategies to meet evolving consumer needs. By integrating market size assessments, consumer behavior trends, and competitive landscape insights, the report provides a comprehensive view of current market dynamics and clearly identifies the key factors shaping future growth.

Key Players in the Global PD-1 and PD-L1 Inhibitors Market Include

Merck

Bristol-Myers Squibb

Pfizer

Sanofi

Regeneron Pharmaceuticals

Roche

AstraZeneca

Hengrui Medicine

Beigene

Innovent Biologics

Junshi Biosciences

Akeso

Alphamab Oncology

PD-1 and PD-L1 Inhibitors Product Segmentation by Type

PD-1

PD-L1

PD-1 and PD-L1 Inhibitors Product Segmentation by Application

Metastatic Melanoma

Non-small Cell Lung Cancer (NSCLC)

Renal Cell Carcinoma (RCC)

Others

Chapter Scope

Chapter 1: Market Scope, Segmentation by Type and Application, and Industry Status & Outlook

Chapter 2: PD-1 and PD-L1 Inhibitors Industry Environment and Supply Chain Analys: Upstream Supply, Distribution Channels, and Key Customer Analysis

Chapter 3: Porter's Five Forces Analysis of the PD-1 and PD-L1 Inhibitors Industry

Chapter 4: Competitive Landscape of the PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, Pricing, and Regional Distribution Analysis

Chapter 5: In-Depth Analysis of Major PD-1 and PD-L1 Inhibitors Companies: Company Overview, Products, Sales and Revenue, Regional Distribution, Pricing, Gross Margin, and Key Development Metrics

Chapter 6: Regional Analysis of the Global PD-1 and PD-L1 Inhibitors Market: Revenue, Sales, Price, and Future Outlook

Chapter 7: Analysis of Global PD-1 and PD-L1 Inhibitors Segmentation by Product Type: Sales, Revenue, Pricing, and Market Share

Chapter 8: Analysis of Global PD-1 and PD-L1 Inhibitors Segmentation by Product Application: Sales, Revenue, Pricing, and Market Share

Chapter 9: Research Findings and Outlook

Chapter 10: Methodology and Data Sources

Table of Content

1 Market Overview and Current Status Analysis

   1.1 PD-1 and PD-L1 Inhibitors Product Definitions and Scope

   1.2 Global PD-1 and PD-L1 Inhibitors Market Overview: Growth Prospects

       1.2.1 Global PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Trend (2021-2033)

       1.2.2 Global PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Trend (2021-2033)

   1.3 Global PD-1 and PD-L1 Inhibitors Market: Segmentation by Product Type

       1.3.1 Global PD-1 and PD-L1 Inhibitors Market: Market Size by Product Type 2025 VS 2026 VS 2033

       1.3.2 PD-1

       1.3.3 PD-L1

   1.4 Global PD-1 and PD-L1 Inhibitors Market: Segmentation by Product Application

       1.4.1 Global PD-1 and PD-L1 Inhibitors Market: Market Size by Product Application 2025 VS 2026 VS 2033

       1.4.2 Metastatic Melanoma

       1.4.3 Non-small Cell Lung Cancer (NSCLC)

       1.4.4 Renal Cell Carcinoma (RCC)

       1.4.5 Others

   1.5 PD-1 and PD-L1 Inhibitors Market Development Status and Outlook

       1.5.1 PD-1 and PD-L1 Inhibitors Market Status

       1.5.2 PD-1 and PD-L1 Inhibitors Market Opportunities and Outlook Analysis

       1.5.3 PD-1 and PD-L1 Inhibitors Market Challenges and Constraints

2 PD-1 and PD-L1 Inhibitors Industry Environment and Supply Chain Analysis

   2.1 Global Economic Landscape and Market Outlook

   2.2 PD-1 and PD-L1 Inhibitors Industry Analysis: PESTEL Framework

       2.2.1 Political Factors Analysis

       2.2.2 Economic Factors Analysis

       2.2.3 Social Factors Analysis

       2.2.4 Technological Factors Analysis

       2.2.5 Environmental Factors Analysis

       2.2.6 Legal Factors Analysis

   2.3 PD-1 and PD-L1 Inhibitors Supply Chain Analysis

   2.4 PD-1 and PD-L1 Inhibitors Upstream Supply Analysis

       2.4.1 Upstream Industry Overview and Opportunities

       2.4.2 Key Raw Materials Regional Supply Analysis

       2.4.3 Key Raw Materials Price Analysis

       2.4.4 Key Raw Material Suppliers Analysis

   2.5 PD-1 and PD-L1 Inhibitors Midstream Supply Analysis

   2.6 PD-1 and PD-L1 Inhibitors Upstream Supply Analysis

   2.7 Downstream Major Customer Overview

3 Porter's Five Forces Analysis

   3.1 Industry Rivalry and Competition

   3.2 Threat of New Entrants

   3.3 Bargaining Power of Suppliers

   3.4 Bargaining Power of Buyers

   3.5 Threat of Substitutes

4 Competitive Landscape: Global Key Players

   4.1 Global PD-1 and PD-L1 Inhibitors Market Competitive Landscape Analysis (2021-2026)

       4.1.1 Global PD-1 and PD-L1 Inhibitors Market: Revenue of Key Player (2021-2026)

       4.1.2 Global PD-1 and PD-L1 Inhibitors Market: Sales Volume of Key Players (2021-2026)

       4.1.3 Global PD-1 and PD-L1 Inhibitors Market: Sales Price of Key Players

   4.2 Global PD-1 and PD-L1 Inhibitors Market: Competitive Tiers and Market Dynamic

       4.2.1 Global PD-1 and PD-L1 Inhibitors Market: Competitive Tiers of Key Players

       4.2.2 Global PD-1 and PD-L1 Inhibitors Market Key Players: Headquarter Location and Key Area Served

       4.2.3 Market Dynamic

5 Key Players Profiles

   5.1 Merck

       5.1.1 Merck Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.1.2 Merck PD-1 and PD-L1 Inhibitors Features and Details

       5.1.3 Merck PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.1.4 Merck PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.1.5 Merck Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.2 Bristol-Myers Squibb

       5.2.1 Bristol-Myers Squibb Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Features and Details

       5.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.2.5 Bristol-Myers Squibb Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.3 Pfizer

       5.3.1 Pfizer Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.3.2 Pfizer PD-1 and PD-L1 Inhibitors Features and Details

       5.3.3 Pfizer PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.3.4 Pfizer PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.3.5 Pfizer Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.4 Sanofi

       5.4.1 Sanofi Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.4.2 Sanofi PD-1 and PD-L1 Inhibitors Features and Details

       5.4.3 Sanofi PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.4.4 Sanofi PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.4.5 Sanofi Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.5 Regeneron Pharmaceuticals

       5.5.1 Regeneron Pharmaceuticals Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.5.2 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Features and Details

       5.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.5.5 Regeneron Pharmaceuticals Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.6 Roche

       5.6.1 Roche Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.6.2 Roche PD-1 and PD-L1 Inhibitors Features and Details

       5.6.3 Roche PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.6.4 Roche PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.6.5 Roche Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.7 AstraZeneca

       5.7.1 AstraZeneca Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.7.2 AstraZeneca PD-1 and PD-L1 Inhibitors Features and Details

       5.7.3 AstraZeneca PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.7.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.7.5 AstraZeneca Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.8 Hengrui Medicine

       5.8.1 Hengrui Medicine Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.8.2 Hengrui Medicine PD-1 and PD-L1 Inhibitors Features and Details

       5.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.8.5 Hengrui Medicine Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.9 Beigene

       5.9.1 Beigene Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.9.2 Beigene PD-1 and PD-L1 Inhibitors Features and Details

       5.9.3 Beigene PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.9.4 Beigene PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.9.5 Beigene Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.10 Innovent Biologics

       5.10.1 Innovent Biologics Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.10.2 Innovent Biologics PD-1 and PD-L1 Inhibitors Features and Details

       5.10.3 Innovent Biologics PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.10.4 Innovent Biologics PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.10.5 Innovent Biologics Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.11 Junshi Biosciences

       5.11.1 Junshi Biosciences Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.11.2 Junshi Biosciences PD-1 and PD-L1 Inhibitors Features and Details

       5.11.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.11.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.11.5 Junshi Biosciences Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.12 Akeso

       5.12.1 Akeso Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.12.2 Akeso PD-1 and PD-L1 Inhibitors Features and Details

       5.12.3 Akeso PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.12.4 Akeso PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.12.5 Akeso Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

   5.13 Alphamab Oncology

       5.13.1 Alphamab Oncology Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

       5.13.2 Alphamab Oncology PD-1 and PD-L1 Inhibitors Features and Details

       5.13.3 Alphamab Oncology PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

       5.13.4 Alphamab Oncology PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

       5.13.5 Alphamab Oncology Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

6 Global PD-1 and PD-L1 Inhibitors Market: Regional Insights

   6.1 Global PD-1 and PD-L1 Inhibitors Market Size by Key Regions: 2025 VS 2026 VS 2033

       6.1.1 Global PD-1 and PD-L1 Inhibitors Market: Revenue and Market Share by Regions (2021-2026)

       6.1.2 Global PD-1 and PD-L1 Inhibitors Market: Revenue Forecasts by Regions (2027-2033)

   6.2 Global PD-1 and PD-L1 Inhibitors Market: Sales Volume by Key Regions 2025 VS 2026 VS 2033

       6.2.1 Global PD-1 and PD-L1 Inhibitors Market: Sales Volume and Market Share by Regions (2021-2026)

       6.2.2 Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Forecasts by Regions (2027-2033)

   6.3 United States PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.4 China PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.5 Germany PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.6 Japan PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.7 France PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.8 United Kingdom PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.9 Italy PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.10 South Korea PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.11 Southeast Asia PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.12 India PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.13 Middle East and Africa PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

   6.14 Latin America PD-1 and PD-L1 Inhibitors Market: Sales Volume, Revenue, and Growth Forecasts (2021-2033)

7 Global PD-1 and PD-L1 Inhibitors Market: Segmentation by Product Type

   7.1 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Type: Revenue and Growth Forecasts (2021-2033)

   7.2 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Type: Sales Volume and Growth Forecasts (2021-2033)

   7.3 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Type: Price and Forecasts (2021-2033)

8 Global PD-1 and PD-L1 Inhibitors Market: Segmentation by Product Application

   8.1 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Application: Revenue and Growth Forecasts (2021-2033)

   8.2 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Application: Sales Volume and Growth Forecasts (2021-2033)

   8.3 Global PD-1 and PD-L1 Inhibitors Market Segmentation by Product Application: Price and Forecasts (2021-2033)

9 Research Findings and Outlook

10 Methodology

   10.1 Research Approach and Modeling

   10.2 Data Sources

       10.2.1 Primary Research

       10.2.2 Secondary Research

   10.3 Disclaimer

List of Tables

Table 1： Global PD-1 and PD-L1 Inhibitors Market: Market Size by Product Type 2025 VS 2026 VS 2033 (USD Million)

Table 2： Global PD-1 and PD-L1 Inhibitors Market: Market Size by Product Application 2025 VS 2026 VS 2033 (USD Million)

Table 3： Key Raw Materials Price

Table 4： Key Raw Material Suppliers List

Table 5： Key Downstream Customers List

Table 6： Global PD-1 and PD-L1 Inhibitors Market: Revenue of Key Players (2021-2026) & (USD Million)

Table 7： Global PD-1 and PD-L1 Inhibitors Market: Revenue Market Share of Key Players (2021-2026)

Table 8： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume of Key Players (2021-2026) & (K Unit)

Table 9： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Market Share of Key Players (2021-2026)

Table 10： Global PD-1 and PD-L1 Inhibitors Market Key Players: Headquarter Location and Key Area Served

Table 11： Market Mergers & Acquisitions, Expansion

Table 12： Merck Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 13： Merck PD-1 and PD-L1 Inhibitors Features and Details

Table 14： Merck PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 15： Merck PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 16： Merck Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 17： Bristol-Myers Squibb Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 18： Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Features and Details

Table 19： Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 20： Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 21： Bristol-Myers Squibb Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 22： Pfizer Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 23： Pfizer PD-1 and PD-L1 Inhibitors Features and Details

Table 24： Pfizer PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 25： Pfizer PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 26： Pfizer Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 27： Sanofi Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 28： Sanofi PD-1 and PD-L1 Inhibitors Features and Details

Table 29： Sanofi PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 30： Sanofi PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 31： Sanofi Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 32： Regeneron Pharmaceuticals Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 33： Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Features and Details

Table 34： Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 35： Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 36： Regeneron Pharmaceuticals Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 37： Roche Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 38： Roche PD-1 and PD-L1 Inhibitors Features and Details

Table 39： Roche PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 40： Roche PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 41： Roche Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 42： AstraZeneca Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 43： AstraZeneca PD-1 and PD-L1 Inhibitors Features and Details

Table 44： AstraZeneca PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 45： AstraZeneca PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 46： AstraZeneca Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 47： Hengrui Medicine Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 48： Hengrui Medicine PD-1 and PD-L1 Inhibitors Features and Details

Table 49： Hengrui Medicine PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 50： Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 51： Hengrui Medicine Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 52： Beigene Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 53： Beigene PD-1 and PD-L1 Inhibitors Features and Details

Table 54： Beigene PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 55： Beigene PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 56： Beigene Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 57： Innovent Biologics Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 58： Innovent Biologics PD-1 and PD-L1 Inhibitors Features and Details

Table 59： Innovent Biologics PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 60： Innovent Biologics PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 61： Innovent Biologics Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 62： Junshi Biosciences Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 63： Junshi Biosciences PD-1 and PD-L1 Inhibitors Features and Details

Table 64： Junshi Biosciences PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 65： Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 66： Junshi Biosciences Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 67： Akeso Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 68： Akeso PD-1 and PD-L1 Inhibitors Features and Details

Table 69： Akeso PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 70： Akeso PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 71： Akeso Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 72： Alphamab Oncology Company Profile Overview (Core Business, Total Employee, Sales Network and Competitors)

Table 73： Alphamab Oncology PD-1 and PD-L1 Inhibitors Features and Details

Table 74： Alphamab Oncology PD-1 and PD-L1 Inhibitors Market Data: Revenue, Sales Volume, Price and Gross Margin 2021-2026

Table 75： Alphamab Oncology PD-1 and PD-L1 Inhibitors Product Revenue by Geographic Area

Table 76： Alphamab Oncology Key Performance Indicators (KPIs) Assessment (Company Size, R&D Investment, International Revenue Contribution, PD-1 and PD-L1 Inhibitors Market Position）

Table 77： Global PD-1 and PD-L1 Inhibitors Market Size by Key Regions: 2025 VS 2026 VS 2033 (USD Million)

Table 78： Global PD-1 and PD-L1 Inhibitors Market: Revenue by Regions (2021-2026) & (USD Million)

Table 79： Global PD-1 and PD-L1 Inhibitors Market: Revenue Market Share by Regions (2021-2026)

Table 80： Global PD-1 and PD-L1 Inhibitors Market: Revenue Forecasts by Regions (2027-2033) & (USD Million)

Table 81： Global PD-1 and PD-L1 Inhibitors Market: Revenue Market Share Forecasts by Regions (2027-2033)

Table 82： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume by Key Regions 2025 VS 2026 VS 2033 & (K Unit)

Table 83： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume by Regions (2021-2026) & (K Unit)

Table 84： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Market Share by Regions (2021-2026)

Table 85： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Forecasts by Regions (2027-2033) & (USD Million)

Table 86： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Market Share Forecasts by Regions (2027-2033)

List of Figures

Figure 1： PD-1 and PD-L1 Inhibitors Picture Scope

Figure 2： Global PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Trend (2021-2033) & (USD Million)

Figure 3： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Trend (2021-2033) & (K Unit)

Figure 4： Global PD-1 and PD-L1 Inhibitors Market Share by Product Type 2026 & 2033

Figure 5： Global PD-1 and PD-L1 Inhibitors Market Share by Product Application 2026 & 2033

Figure 6： PD-1 Product Analysis

Figure 7： PD-L1 Product Analysis

Figure 8： Metastatic Melanoma Overview

Figure 9： Non-small Cell Lung Cancer (NSCLC) Overview

Figure 10： Renal Cell Carcinoma (RCC) Overview

Figure 11： Others Overview

Figure 12： Global Economic Landscape and Market Outlook

Figure 13： PD-1 and PD-L1 Inhibitors Industry Analysis: PESTEL Framework

Figure 14： PD-1 and PD-L1 Inhibitors Supply Chain Overview

Figure 15： PD-1 and PD-L1 Inhibitors Porter's Five Forces Analysis

Figure 16： Global PD-1 and PD-L1 Inhibitors Market: Revenue Market Share of Key Players in 2025

Figure 17： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Market Share of Key Players in 2025

Figure 18： Global PD-1 and PD-L1 Inhibitors Market: Sales Price of Key Players in 2025 (USD/Unit)

Figure 19： Global PD-1 and PD-L1 Inhibitors Industry Competition Landscape

Figure 20： Global PD-1 and PD-L1 Inhibitors Market: Revenue Market Share by Regions (2021 VS 2026)

Figure 21： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Market Share by Regions (2021 VS 2026)

Figure 22： United States PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 23： United States PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 24： China PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 25： China PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 26： Germany PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 27： Germany PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 28： Japan PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 29： Japan PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 30： France PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 31： France PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 32： United Kingdom PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 33： United Kingdom PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 34： Italy PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 35： Italy PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 36： South Korea PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 37： South Korea PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 38： Southeast Asia PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 39： Southeast Asia PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 40： India PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 41： India PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 42： Middle East and Africa PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 43： Middle East and Africa PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 44： Latin America PD-1 and PD-L1 Inhibitors Market: Sales Volume and Growth Forecasts (2021-2033) & (K Unit)

Figure 45： Latin America PD-1 and PD-L1 Inhibitors Market: Revenue and Growth Forecasts (2021-2033) & (USD Million)

Figure 46： Global PD-1 and PD-L1 Inhibitors Market: Revenue by Product Type 2021-2026 & (USD Million)

Figure 47： Global PD-1 and PD-L1 Inhibitors Market: Revenue Forecast by Product Type (2027-2033) & (USD Million)

Figure 48： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume by Product Type 2021-2026 & (K Unit)

Figure 49： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Forecasts by Product Type (2027-2033) & (K Unit)

Figure 50： Global PD-1 and PD-L1 Inhibitors Market: Price and Forecasts by Product 2021-2033 & (USD/Unit)

Figure 51： Global PD-1 and PD-L1 Inhibitors Market: Revenue by Product Application 2021-2026 & (USD Million)

Figure 52： Global PD-1 and PD-L1 Inhibitors Market: Revenue Forecast by Product Application (2027-2033) & (USD Million)

Figure 53： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume by Product Application 2021-2026 & (K Unit)

Figure 54： Global PD-1 and PD-L1 Inhibitors Market: Sales Volume Forecasts by Product Application (2027-2033) & (K Unit)

Figure 55： Global PD-1 and PD-L1 Inhibitors Market: Price and Forecasts by Product 2021-2033 & (USD/Unit)

Figure 56： Top-Down and Bottom-Up Approaches

Research Methodology

The market forecasts presented in this report are based on the following key assumptions: (i) the global social, economic, and political environment remains broadly stable throughout the forecast period; (ii) the industry’s key growth drivers continue to support market expansion, including technological progress, infrastructure development, favorable policy environments, and sustained downstream demand; and (iii) no major force majeure events, significant regulatory disruptions, or other unforeseen circumstances occur that could materially affect the overall market outlook.

In compiling and preparing this DRIVEINTEL RESEARCH report, the following primary and secondary research approaches were adopted to collect, analyze, and validate information from multiple sources. Primary research involved detailed interviews and discussions with key industry participants, market players, and experts across the value chain to obtain first-hand market insights, industry developments, and future growth expectations. Secondary research involved the review and analysis of publicly available information, supported by DRIVEINTEL RESEARCH’s proprietary research database, including government statistics, industry association publications, company reports, regulatory documents, and independent research materials. The combination of multiple research methods enables comprehensive data verification and enhances the accuracy, consistency, and credibility of the market analysis and forecasts.

The analysis presented in this report is conducted based on widely recognized strategic and market analysis frameworks, including industry lifecycle analysis, PESTEL analysis, Porter’s Five Forces, SWOT analysis, the BCG matrix, and Porter’s Diamond Model. These frameworks are applied to evaluate key market factors, including supply and demand dynamics, competitive landscape, industry profitability, and value chain evolution. The analysis incorporates insights from long-term industry monitoring, proprietary data accumulation, and continuous market tracking to identify key trends and provide forward-looking market perspectives. The report covers overall market size, segment analysis, import and export dynamics, demand patterns, and detailed assessments of major industry participants. The findings are designed to provide strategic insights and practical guidance to support informed decision-making in an increasingly complex and competitive market environment.

Data Sources

When preparing DRIVEINTEL Research reports, the team gathers information from a variety of sources and ensures the accuracy and reliability of the data through verification and cross-checking. The research methodology consists of two main approaches: (i) primary research, which includes interviews and discussions with leading industry players and experts to obtain firsthand insights into industry trends and developments; and (ii) secondary research, which involves analyzing publicly available materials using DEWENTE’s proprietary research database, including company reports, independent studies, and relevant market data.

Primary Research

DRIVEINTEL’s research framework is anchored in the systematic collection of primary data. Core methodologies include structured surveys, in-depth corporate interviews, and on-site observations, enabling direct engagement with stakeholders across all tiers of the global value chain. Key interlocutors encompass CEOs, senior management, marketing and technical leaders, industry experts, as well as upstream and downstream partners such as clients, distributors, and suppliers. Through this approach, DRIVEINTEL has established a comprehensive network of domain experts spanning the full supply chain. By integrating these insights with real-time market intelligence, industry trends, and multifaceted perspectives, the firm ensures its analyses are rigorous, holistic, and directly actionable for strategic decision-making.

Secondary Research

In compiling the secondary research data for this study, DRIVEINTEL performed an in-depth secondary research process, tapping into a wide range of trusted sources. These included corporate reports, SEC filings, investor presentations, industry publications, and authorization databases, as well as government and association journals. Our approach, driven by a clear research framework and supported by robust internal expertise and data resources, ensures that the collected information is both reliable and comprehensive.